ZAHIDA SAIRITUPA: Open Payments
NPI 1831120674 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,131 in 169 payments from 17 companies in 2025. Trend: 2023 $3,794 · 2024 $4,235 · 2025 $4,131
Food & beverage: $4,131
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 49 | $871 |
| Neurocrine BioSciences, Inc. | 16 | $620 |
| Teva Pharmaceuticals USA, Inc. | 15 | $478 |
| Otsuka America Pharmaceutical, Inc. | 30 | $411 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $312 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $269 |
| Axsome Therapeutics, Inc. | 6 | $237 |
| Janssen Pharmaceuticals, Inc | 8 | $203 |
| Corium, LLC | 11 | $199 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $169 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, REXULTI, Auvelity, INVEGA SUSTENNA, AUSTEDO XR, Azstarys.
Industry payments across CT — which companies pay providers there.
